Participants 76 114 4
patients with hematologic malignancies
Participants 325 528 8
Seventy immunocompromised febrile patients with hematologic malignancies were randomly assigned to either a vancomycin therapeutic drug monitoring group (TDM group; n = 37) or to a control group (n = 33)
